Skip to main content

Table 2 Incidence of private purchasing in 2022 for the top 30 active ingredients impacting contracted pharmaceutical expenditure, as per Table 3 of the latest Osmed report 2022. Data source: IQVIA

From: Out-of-pocket pharmaceutical expenditure and potential misuse of public resources - analysis in the Italian context

 

ITALY

MACRO CENTRAL AREA

MACRO NORD AREA

MACRO SUD AREA

Atc

Active Principle

Ddd X 1000 Inhabitants Private Purchases

% Incidence of Private Purchases

Ddd X 1000 Inhabitants Private Purchases

% Incidence of Private Purchases

Ddd X 1000 Inhabitants Private Purchases

% Incidence of Private Purchases

Ddd X 1000 Inhabitants Private Purchases

% Incidence of Private Purchases

A02BC01

OMEPRAZOLE

43,08

17,2

210,81

18,02

275,11

19,94

356,11

14,88

A02BC02

PANTOPRAZOLO

68,45

16,65

432,93

21,17

528,81

16,14

447,12

15,04

A02BC03

LANSOPRAZOLO

27,99

15,45

152,94

16,93

210,38

11,97

195,12

14,01

A02BC05

ESOMEPRAZOLO

42,6

18,58

212,5

22,82

332,12

16,21

319,5

17,95

A07AA11

RIFAXIMINA

2,91

11,94

17,1

12,83

20,68

12,16

19,03

10,12

A07EC02

MESALAZINA

4,99

7,33

28,36

7,99

31,4

6,08

39,95

7,88

A10AB05

INSULINA ASPART

0,64

1,92

3,51

1,63

1,27

0,55

7,59

2,82

A10BA02

METFORMINA

37,08

11,93

149,63

9,9

279,59

11,83

250,02

10,18

A11CC05

COLECALCIFEROLO

497,18

26,12

2.693,28

31,32

4.905,11

28,06

2.775,67

20,12

B01AB05

ENOXAPARINA

3,07

9,24

10,31

11,65

17,02

10,51

28,16

12,56

C07AB07

BISOPROLOLO

13,4

8,14

53,39

6,85

117,25

7,88

92,79

7,92

C08CA01

AMLODIPINA

24,09

6,79

121,01

5,98

199,51

6,44

149,2

7,18

C09AA05

RAMIPRIL

78,56

9,76

379,39

8,38

597,6

8,42

494,45

10,6

C09CA08

OLMESARTAN MEDOXOMIL

11,99

5,74

58,27

5,65

88,36

5,54

90,43

4,97

C09DX03

OLMESARTAN MEDOXOMIL- AMLODI

0,07

43,75

0,45

47,37

0,63

38,41

0,38

46,91

C10AA01

SIMVASTATINA

13,31

8,98

63,24

8,12

107,89

9,05

73,43

7,11

C10AA05

ATORVASTATINA

23,14

3,71

111,52

3,47

169,86

3,23

170,4

3,88

C10AA07

ROSUVASTATINA

21,79

10,48

126,92

11,29

140,83

8,1

153,79

11,35

C10AX06

OMEGA-3-TRIGLICERIDI INCLUSI

4,33

12,63

23,17

12,67

38,57

16,38

26,51

9,39

J01CR02

AMOXICILLINA ED INIBITORE DELLE LATTAMASI

25,14

29

118,54

26,59

214,78

31,57

152,7

23

L02BG04

LETROZOLO

0,92

4,07

4,82

4,5

3,45

1,7

9,43

5,16

N02AB03

FENTANIL

0,55

7,02

2,82

7,16

4,43

5,29

3,98

7,39

N02BF02

PREGABALIN

3,49

10,82

18,55

10,79

31

10,16

19,9

9,57

N03AX14

LEVETIRACETAM

2,07

7,18

11,67

8,1

12,93

5,25

14,35

6

R03AK07

FORMOTEROLO E BUDESONIDE

1,38

5,58

6,41

5,71

9,95

4,44

12,5

7,73

R03AK08

FORMOTEROLO E BECLOMETASONE

2,39

4,76

12,35

4,51

14,04

3

25,85

8,49

R03AK10

VILANTEROLO E FLUTICASONE FU

0,71

1,64

4,28

1,76

4,62

1,41

6,99

2,17

  1. DDD = Defined Daily Dose (source. https://www.aifa.gov.it/documents/20142/1967301/Rapporto-OsMed-2022.pdf)
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us